Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles
Top Cited Papers
- 1 January 2006
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 85 (1) , 112-120
- https://doi.org/10.1016/j.fertnstert.2005.07.1292
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Emerging drugs in assisted reproductionEmerging Drugs, 2005
- GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized studyHuman Reproduction, 2005
- Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profileHuman Reproduction, 2005
- Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control studyFertility and Sterility, 2004
- The Pathogenesis of the Ovarian Hyperstimulation SyndromeNew England Journal of Medicine, 2003
- Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?Human Reproduction, 2002
- Prevention and management of ovarian hyperstimulation syndromeCurrent Obstetrics & Gynaecology, 2002
- Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelinHuman Reproduction, 2000
- Ovarian hyperstimulation syndrome (OHSS): how much do we really know about it?European Journal of Obstetrics & Gynecology and Reproductive Biology, 1994
- Ovarian Hyperstimulation SyndromeObstetrical & Gynecological Survey, 1989